Results 11 to 20 of about 3,222,323 (307)

Antiviral therapy: a perspective

open access: yesDrug Design, Development and Therapy, 2016
This paper discusses extracorporeal removal of viral particles and their antigens from the blood as an auxiliary therapy. This hypothesis has not been reported before. In some chronic blood-borne viral infections, the virus remains systemic and persistent for extended periods of time, with adverse effects that weaken the immune system.
Shahidi Bonjar AH
openaire   +6 more sources

Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism [PDF]

open access: yes, 2003
Background. Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of chronic active hepatitis C. Polymorphisms in the promoter region of the TNF-alpha gene can alter the TNF-alpha expression and modify the host immune response.
Konig, A.   +8 more
core   +1 more source

Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic Hepatitis B virus infected patients [PDF]

open access: yes, 2012
Natural killer (NK) cells play a critical role in innate antiviral immunity, but little is known about the impact of antiviral therapy on the frequency of NK cell subsets.
Xiumei Chi   +25 more
core   +1 more source

Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA

open access: yesBMC Infectious Diseases, 2019
Background Chronic infection with hepatitis B virus (HBV) is a serious global health problem. Persistence of the virus occurs as a result of stability of the replication intermediate comprising covalently closed circular DNA (cccDNA).
Kristie Bloom   +5 more
doaj   +1 more source

Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives

open access: yesAntiviral Therapy, 2023
In endemic areas, hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfection is common, and patients with coinfection have a higher risk of developing liver disease such as hepatocellular carcinoma, liver fibrosis and cirrhosis.
Quratulain Maqsood   +6 more
doaj   +1 more source

Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case–control study from Uganda and South Africa

open access: yesAntiviral Therapy, 2022
Background Relationships between distinct antiretroviral therapy (ART) adherence patterns and risk of drug resistance are not well understood. Methods We conducted a nested case–control analysis within a longitudinal cohort study of individuals ...
Anisha Tyagi   +14 more
doaj   +1 more source

Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi

open access: yesAntiviral Therapy, 2022
Background Information on HIV drug resistance (HIVDR) prevalence in people newly diagnosed with HIV is limited. We implemented a cross-sectional study to estimate HIVDR prevalence among pregnant women recently infected with HIV in Malawi.
George Bello   +21 more
doaj   +1 more source

Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study

open access: yesAntiviral Therapy, 2022
Background Tenofovir alafenamide (TAF) is a new anti-hepatitis B virus nucleotide analogue that can cause dyslipidaemia in AIDS patients, but the effect of TAF on blood lipids in patients with chronic hepatitis B (CHB) is unknown.
Yeqiong Zhang   +7 more
doaj   +1 more source

Inhibition of chikungunya virus replication by N-ω-Chloroacetyl-L-Ornithine in C6/36, Vero cells and human fibroblast BJ

open access: yesAntiviral Therapy, 2023
Background Polyamines are involved in several cellular processes and inhibiting their synthesis affects chikungunya virus (CHIKV) replication and translation, and, therefore, reduces the quantity of infectious viral particles produced.
Lucero Rojas-Luna   +7 more
doaj   +1 more source

A convenient method to generate and maintain poly(A)-encoding DNA sequences required for in vitro transcription of mRNA

open access: yesBioTechniques, 2019
Generating mRNA in vitro to encode therapeutic or cell-modifying proteins is rapidly gaining favor. An important factor that determines efficiency of translation from in vitro transcribed mRNA is the length of the 3′ poly(A) sequence.
Patrick Arbuthnot   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy